NEUROCRINE BIOSCIENCES INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
NEUROCRINE BIOSCIENCES INC (NBIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.90 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-11
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.90M shares, a 26.67% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.50M shares, a 21.05% decline from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.90M shares, a 13.64% decline from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.20M shares, a 22.22% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|
| 2025-12-31 | 1.90M shares 10-K · filed 2026-02-11 |
| 2024-12-31 | 1.50M shares 10-K · filed 2025-02-10 |
| 2023-12-31 | 1.90M shares 10-K · filed 2024-02-09 |
| 2022-12-31 | 2.20M shares 10-K · filed 2023-02-09 |
| 2021-12-31 | 1.80M shares 10-K · filed 2022-02-11 |
| 2020-12-31 | 1.30M shares 10-K · filed 2021-02-05 |
| 2019-12-31 | 1.42M shares 10-K · filed 2020-02-07 |
| 2018-12-31 | 1.04M shares 10-K · filed 2020-02-07 |
| 2017-12-31 | 1.81M shares 10-K · filed 2020-02-07 |
| 2016-12-31 | 1.08M shares 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |